Ethanol in tears can cause development of ocular diseases

Article

Orally administered ethanol is secreted into tears and can cause the development of ocular surface diseases.

Orally administered ethanol is secreted into tears and can cause the development of ocular surface diseases, claims a study in the journal Ophthalmology.

The case control study, led by Dr Joo Hyun Kim, Department of Ophthalmology, Hallym University College of Medicine, Seoul, Korea, included 20 healthy male subjects with no prior ocular surface diseases. Ten participants received ethanol orally at 8 pm for two hours and ten were placed in the control group.

The main outcome measures were tear osmolarity, ethanol concentration in tears and serum, Schirmer's test results, tear film break-up time (TBUT), corneal punctuate erosion and corneal sensitivity. Tear film and ocular surface were measured at 6 pm before drinking, at midnight and at 6 am and 8 am the following morning.

Mean tear osmolarity increased in the ethanol group, compared to the control group. The ethanol group demonstrated a significantly shorter TBUT after drinking alcohol.

The fluorescein staining scores were significantly higher in the alcohol group compared to the control group at 6 am and 8 am. However, there were no changes in corneal sensitivity or Schirmer's test results.

Ethanol in tears caused the development hyperosmolarity and reduced TBUT. These changes could worsen signs and symptoms in patients with ocular surface disease.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.